Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$44.03 USD
-0.08 (-0.18%)
Updated May 17, 2024 03:59 PM ET
After-Market: $44.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMY 44.03 -0.08(-0.18%)
Will BMY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Walmart Earnings & the State of the Consumer
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Other News for BMY
Bristol-Myers publishes data on Sotyktu,CheckMate; gets FDA approval
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
May's 5 Dividend Growth Stocks With 5.49%+ Yields
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
Hold Rating on Bristol-Myers Squibb Amid Mounting Competition and Flat Growth Projections